SCHEMBL4137264

SCHEMBL4137264

C[C@](O)(CBr)C(=O)Nc1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.74

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.74
PGR P06401 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4137272 1.00 AR (0.74) ARPGR
SCHEMBL14252941 0.86 AR (0.74) ARPGR
SCHEMBL20646267 0.85 AR (1.00) AR
SCHEMBL20326887 0.85 AR (1.00) AR
SCHEMBL12712751 0.85 AR (0.73) AR
SCHEMBL4123404 0.84 AR (0.64) ARPGR
SCHEMBL13695983 0.84 AR (0.54) AR
SCHEMBL9891509 0.83 AR (0.63) ARPGR
SCHEMBL4279811 0.82 AR (0.68) AR
SCHEMBL110581 0.82 AR (0.68) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090226368-A1 Androgen-Receptor (AR) Ligands for Use in the Treatment and Diagnosis of AR-Related Pathologies MEDICAL RESEARCH FUND AT THE TEL AVIV SOURASKY MEDICAL CENTER (IL) 2009-09-10 US disclosed
EP-1957059-A1 ANDROGEN-RECEPTOR (AR) LIGANDS FOR USE IN THE TREATMENT AND DIAGNOSIS OF AR-RELATED PATHOLOGIES HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2008-08-20 EP disclosed
WO-2007057909-A1 ANDROGEN-RECEPTOR (AR) LIGANDS FOR USE IN THE TREATMENT AND DIAGNOSIS OF AR-RELATED PATHOLOGIES HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226368-A1 Androgen-Receptor (AR) Ligands for Use in the Treatment and Diagnosis of AR-Related Pathologies AR, SHBG, ESRRB AR 1/4885PGR 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.